News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “ Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022”, the global ADCs market is experiencing an astounding growth due to increasing cancer epidemics globally resulting in increasing demand for ADCs. Cancer constitutes a key challenge to development, deflating social and economic advancements throughout the world. According to American cancer Society, approximately 8 million people globally die of cancer every year. Additionally, in 2016, an estimated 1,685,210 new cases of cancer were diagnosed in the United States and 595,690 people were estimated to die from the disease. In such a scenario, ADCs have emerged as one of the chief revenue generator for the pharmaceutical companies working individually or in collaboration with cancer research institutes for development of ADCs. These include Seattle Genetics, Roche, ImmunoGen, Bayer, Novartis, Oxford BioTherapeutics, Takeda Pharma, amongst others. The ADCs market globally is expected to become much more organized and consolidated with the technological advancements and debut makers that are entering into the ADC industry.
 
According to RNCOS, the Global ADC industry is expected to grow at a very high double digit CAGR during 2016-2022. Rising cancer epidemics, increasing demand for ADCs, advancements in linking technology are some of the major factors which will administer the growth of this industry.
 
Research Analysis and Highlights
 
The report is dispersed across 122 pages and provides an in-depth research and rational analysis of the current status and future prospects of the Global ADCs Industry. The report also provides a clear picture of the current status of ADCs pipeline followed by emerging trends and developments. Additionally, the study includes all ADCs represented that are under various clinical phases of development. The report further highlights segmentation of the ADC pipeline based on clinical phase, cancer indication, linker used, drug, and technology, as well as the individual share of each segment. At the end, with special focus on key players in ADCs industry, the research provides valuable information to the investors and debut makers who are looking forward to enter in this market.
 
Some of the salient features of the report include:
 
•        Advancements in Linker Technology used for developing ADCs
•        Rising demand for ADCs
•        ADC Market forecasts to 2022
•        Current analysis of potential ADCs in pipeline
 
Some of our Related Reports are:
 
        Global Antibody Drug Conjugate Market Outlook 2020
        Global Antibody Drug Conjugate Market Outlook 2018

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM894.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm